Modulim Announces CE Mark of Clarifi Imaging System for Microvascular Assessment
The Californer/10107064

IRVINE, Calif.--(BUSINESS WIRE)--Modulim, the global leader in optical imaging solutions for the non-invasive assessment of tissue and vascular health, announced today that Clarifi^® has received CE Mark certification. This allows Modulim to now expand its marketing and distribution throughout Europe and apply for registration in other international markets that recognize the CE Mark.

Powered by Spatial Frequency Domain Imaging (SFDI), a patented optical imaging technology, Clarifi is the newest advancement for assessing tissue and microvascular function by quantitatively mapping tissue oxygenation and perfusion at the point-of-care. Clarifi's fully-integrated solution is rapidly gaining acceptance by clinicians across the continuum of care for assessing potential circulatory compromise to manage and treat diabetic, venous and pressure ulcers, acute and chronic wounds, burns, and amputations.

More on The Californer

• Leon Youngblood Consultants streams Inaugural Concert featuring President Joe Biden & VP K. Harris
• PG&E Restores Nearly All Customers Following Historic Windstorm, Prepares for Winter Snow and Rain Next Week
• Ventura College's Advanced Manufacturing Program is Preparing for the Future
• Universal Credit now available for all your personal loan needs
• CEDC Awards Students with Fernandez Leadership Fund Scholarships

"Obtaining CE marking for the Clarifi Imaging System is a key milestone for Modulim," said David Cuccia, Ph.D., Modulim's President and CTO. "This achievement allows us to expand our addressable market and deliver a complete microvascular assessment solution that helps clinicians prevent lower limb complications in patients with diabetes as well as other life-altering circulatory issues. We are now able to bring our innovative technology to our European clinical partners, and grow our ever expanding image library by reaching the 60 million diabetes patients in the EU."

Clarifi can help clinicians identify potential compromised circulation and pre-ulcerative conditions, before they are visible, so they can implement timely and targeted intervention to prevent costly and deadly complications. Powered by SFDI, Clarifi provides new information that enables healthcare providers in all environments to transition from reactive care to proactive care.

The Clarifi Imaging System demonstrates Modulim's continuing mission to deliver transformative optical solutions that help people live healthier, longer lives.

More on The Californer

• Long Beach: LBC Vaccine Update
• San Jose: San José Mayor Sounds Warning as Another Silicon Valley Company Moves Headquarters
• The World's First Tortilla Chip Beer - Just in Time for Game Day
• FCPT Announces Tax Treatment of 2020 Distributions
• Furin Inhibitor Screening Kit (Fluorometric)

About Modulim

Modulim delivers transformative optical solutions that help people live healthier, longer lives. Clarifi, powered by Spatial Frequency Domain Imaging (SFDI) technology, identifies compromised circulation at the point of care through non-contact rapid microvascular assessment of tissue. Clinicians and healthcare systems are empowered by SFDI images to make proactive, data-driven decisions in a multidisciplinary care setting, in order to reduce lower-limb complications caused by diabetes and peripheral arterial disease. Founded by the inventors of SFDI at the University of California Irvine, Modulim is based in Irvine, CA with a team dedicated to delivering powerful healthcare solutions that elevate and standardize health care delivery, while improving patient outcomes. Modulim is backed by Pangaea Ventures, Fresenius Medical Care Ventures, Grey Sky Venture Partners, Mitsubishi Capital, Hamamatsu Photonics, The Cove Fund at UCI Applied Innovation, and Fouse KK.

Clarifi is a registered trademark of Modulated Imaging (dba Modulim).

---

Show All News | Report Violation